** = Publikationen gelistet in SCI/SSCI/Pubmed
** Pasterk, L; Philipose, S; Eller, K; Marsche, G; Heinemann, A; Schuligoi, R
The EP3 Agonist Sulprostone Enhances Platelet Adhesion But Not Thrombus Formation Under Flow Conditions.
Pharmacology. 2015; 96(3-4):137-143
Doi: 10.1159/000437143
Web of Science
PubMed
FullText
FullText_MUG
** Konya, V; Üllen, A; Kampitsch, N; Theiler, A; Philipose, S; Parzmair, GP; Marsche, G; Peskar, BA; Schuligoi, R; Sattler, W; Heinemann, A
Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking.
J Allergy Clin Immunol. 2013; 131(2):532-40.e1-532-40.e2
Doi: 10.1016/j.jaci.2012.05.008
Web of Science
PubMed
FullText
FullText_MUG
** Sreckovic, I; Birner-Gruenberger, R; Obrist, B; Stojakovic, T; Scharnagl, H; Holzer, M; Scholler, M; Philipose, S; Marsche, G; Lang, U; Desoye, G; Wadsack, C
Distinct composition of human fetal HDL attenuates its anti-oxidative capacity.
Biochim Biophys Acta. 2013; 1831(4):737-746
Doi: 10.1016/j.bbalip.2012.12.015
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Philipose, S; Konya, V; Lazarevic, M; Pasterk, LM; Marsche, G; Frank, S; Peskar, BA; Heinemann, A; Schuligoi, R
Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation.
PLoS One. 2012; 7(8):e40222-e40222
Doi: 10.1371/journal.pone.0040222
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Konya, V; Philipose, S; Bálint, Z; Olschewski, A; Marsche, G; Sturm, EM; Schicho, R; Peskar, BA; Schuligoi, R; Heinemann, A
Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors.
Eur J Immunol. 2011; 41(8):2379-2389
Doi: 10.1002/eji.201141460
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
** Luschnig-Schratl, P; Sturm, EM; Konya, V; Philipose, S; Marsche, G; Fröhlich, E; Samberger, C; Lang-Loidolt, D; Gattenlöhner, S; Lippe, IT; Peskar, BA; Schuligoi, R; Heinemann, A
EP4 receptor stimulation down-regulates human eosinophil function.
Cell Mol Life Sci. 2011; 68(21): 3573-3587.
Doi: 10.1007/s00018-011-0642-5
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
** Mashta, A; Mishra, P; Philipose, S; Tamilzhalagan, S; Mahmud, H; Bhaskar, S; Upadhyay, P
Diagnosis of tuberculosis: the experience at a specialized diagnostic laboratory.
J Negat Results Biomed. 2011; 10(7):16-16
Doi: 10.1186/1477-5751-10-16
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
** Philipose, S; Offner, M; Konya, V; Heinemann, A; Schuligoi, R
PGE2 INHIBITS THROMBOGENESIS VIA THE EP4 RECEPTOR IN A PROTEIN KINASE C MEDIATED PATHWAY
BASIC CLIN PHARMACOL. . 2011; 109: 98-98.-10th Congress of the European Association for Clinical Pharmacology and Therapeutics; JUN 26-29, 2011; Budapest, HUNGARY.
[Poster]
Web of Science
** Sreckovic, I; Birner-Gruenberger, R; Philipose, S; Holzer, M; Marsche, G; Desoye, G; Lang, U; Wadsack, C
APOLIPOPROTEINS (APO) ACCOUNTS FOR THE ANTI-INFLAMMATORY FUNCTION OF FETAL HDL
PLACENTA. 2011; 32(9):A112-A112.-Meeting of the International-Federation-of-Placenta-Associations (IFPA); SEP 14-17, 2011; Geilo, NORWAY.
[Poster]
Web of Science
** Philipose, S; Konya, V; Sreckovic, I; Marsche, G; Lippe, IT; Peskar, BA; Heinemann, A; Schuligoi, R
The Prostaglandin E2 Receptor EP4 Is Expressed by Human Platelets and Potently Inhibits Platelet Aggregation and Thrombus Formation.
Arterioscler Thromb Vasc Biol. 2010; 30(12): 2416-2423.
Doi: 10.1161/ATVBAHA.110.216374
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
** Schuligoi, R; Sturm, E; Luschnig, P; Konya, V; Philipose, S; Sedej, M; Waldhoer, M; Peskar, BA; Heinemann, A
CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases.
Pharmacology. 2010; 85(6): 372-382.
Doi: 10.1159/000313836
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar